The regulatory changes surrounding the weight loss treatment industry are having a large impact on Hims & Hers stock.
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFA23 Nov 2025, 20:45 UTC
AI-generated source summary
The video discusses the stock HIMS. It indicates that HIMS stock price is down 29% over the previous 30 days and identifies three primary factors moving the stock. First, Trump's announcement on weight-loss drug price reductions impacting competition for HIMS. He notes questions about the relationship with Novo Nordisk and discusses the CEO selling shares, which creates skepticism. It calculates an intrinsic value of $43.85 per share, noting an attractive valuation and potential for profit. A chart shows HIMS has Forward P/E of 54.83, and the forward P/OCF is 20.11. The analysis concludes it is a good opportunity and recommends upgrading HIMS to a buy with an intrinsic value near 44.00.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Signals in this source
More Prediction Case Files from Parkev Tatevosian, CFA
Coca-Cola Stock: Buy, Hold, or Sell? | KO Stock Analysis
SoFi Stock Analysis: Buy the Dip?
Should You Buy Micron Stock Instead of Nvidia Stock? | MU Stock vs. NVDA Stock
Should You Buy the Dip in Meta Stock? | META Stock Analysis and Live Earnings Review
Should Passive Income Investors Buy Colgate Palmolive Stock?
Procter & Gamble Stock: Buy, Hold, or Sell? | PG Stock Analysis
Parkev Tatevosian, CFA
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.